Immune therapy of non-small cell lung cancer. The future

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Surgery is the primary lung cancer treatment, but limited operability and mediocre prognosis in many patients necessitate advanced medical therapies.
• Conventional platinum-based chemotherapy has limitations, driving the search for more effective lung cancer treatments.
• Recent advancements in understanding cancer biology have led to novel therapeutic agents, including immunotherapies.

Purpose of the Study:

• To highlight the emergence of immune checkpoint inhibitors as a significant innovation in lung cancer treatment.
• To discuss the potential of anti-PD-1 antibodies in treating metastatic lung cancer.
• To identify critical questions for optimizing anti-PD-1/anti-PD-L1 therapies.

Main Methods:

• Review of initial clinical trials involving anti-PD-1 antibodies in metastatic lung cancer patients.
• Analysis of the biological basis for immune checkpoint blockade in cancer therapy.
• Exploration of potential combination treatment modalities.

Main Results:

• Initial trials with anti-PD-1 antibodies have demonstrated unprecedented efficacy in metastatic lung cancer.
• These immunotherapies represent a remarkable advancement compared to traditional chemotherapy regimens.
• Significant improvements in patient outcomes have been observed in early studies.

Conclusions:

• Immune checkpoint blockade, particularly with anti-PD-1/anti-PD-L1 agents, offers a promising new frontier for lung cancer treatment.
• Key areas for future research include identifying predictive biomarkers for treatment response, evaluating combined treatment strategies (surgery, chemotherapy, ITKs), and enhancing the host immune response through supportive care.